Novel small-molecule therapy of Hodgkin lymphoma

Daniela Buglio; Georgios Georgakis; Anas Younes

doi:10.1586/14737140.7.5.735

Novel small-molecule therapy of Hodgkin lymphoma

Daniela Buglio
, Georgios Georgakis
, Anas Younes

Surgery

University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.

Original language	English
Pages (from-to)	735-740
Number of pages	6
Journal	Expert Review of Anticancer Therapy
Volume	7
Issue number	5
DOIs	https://doi.org/10.1586/14737140.7.5.735
State	Published - May 2007

Keywords

Bcl-2
Bortezomib
HDAC
HSP90
mTOR
Reed-Sternberg

Access to Document

10.1586/14737140.7.5.735

Cite this

@article{8e5983b3cca34ec9aef1520204a2eb16,

title = "Novel small-molecule therapy of Hodgkin lymphoma",

abstract = "The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.",

keywords = "Bcl-2, Bortezomib, HDAC, HSP90, mTOR, Reed-Sternberg",

author = "Daniela Buglio and Georgios Georgakis and Anas Younes",

year = "2007",

month = may,

doi = "10.1586/14737140.7.5.735",

language = "English",

volume = "7",

pages = "735--740",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

number = "5",

}

TY - JOUR

T1 - Novel small-molecule therapy of Hodgkin lymphoma

AU - Buglio, Daniela

AU - Georgakis, Georgios

AU - Younes, Anas

PY - 2007/5

Y1 - 2007/5

N2 - The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.

AB - The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.

KW - Bcl-2

KW - Bortezomib

KW - HDAC

KW - HSP90

KW - mTOR

KW - Reed-Sternberg

UR - https://www.scopus.com/pages/publications/34248512223

U2 - 10.1586/14737140.7.5.735

DO - 10.1586/14737140.7.5.735

M3 - Review article

C2 - 17492936

AN - SCOPUS:34248512223

SN - 1473-7140

VL - 7

SP - 735

EP - 740

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -

Novel small-molecule therapy of Hodgkin lymphoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this